Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7461191 | 0.84 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL10493641 | 0.79 | — | — | |
| SCHEMBL7462125 | 0.78 | — | — | |
| SCHEMBL7623165 | 0.76 | — | — | |
| SCHEMBL10482473 | 0.76 | — | — | |
| SCHEMBL10780011 | 0.74 | — | — | |
| SCHEMBL8994496 | 0.74 | — | — | |
| SCHEMBL28918664 | 0.74 | — | — | |
| SCHEMBL21066951 | 0.72 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL27882980 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3280402-B1 | TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING | BIOMENDICS LLC (US) | 2024-06-05 | — | — | EP | disclosed |
| CN-107847466-B | Formulations and methods for modulating wound healing | 贝欧曼蒂克丝公司 | 2024-02-06 | — | — | CN | disclosed |
| US-11786481-B2 | Formulation and process for modulating wound healing | BioMendics, LLC (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230130617-A1 | PROCESS FOR IMPROVED OPIOID SYNTHESIS | RHODES TECHNOLOGIES (US) | 2023-04-27 | — | — | US | disclosed |
| US-20220296538-A1 | Substituted Tolans for the Modulation of Microbial Colonization | BioMendics, LLC (US) | 2022-09-22 | — | — | US | disclosed |
| US-11351126-B2 | Substituted tolans for the modulation of microbial colonization | BioMendics, LLC (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210228501-A1 | Formulation and Process for Modulating Wound Healing | BioMendics, LLC (US) | 2021-07-29 | — | — | US | disclosed |
| CN-111526873-A | Substituted tolanes for regulating microbial colonization | 生物曼迪克斯有限责任公司 | 2020-08-11 | — | — | CN | disclosed |
| US-20200206154-A1 | Substituted Tolans for the Modulation of Microbial Colonization | BioMendics, LLC (US) | 2020-07-02 | — | — | US | disclosed |
| EP-2880033-B1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2020-06-17 | — | — | EP | disclosed |
| WO-2011103932-A1 | A PROCESS FOR THE PREPARATION OF SUBSTITUTED PROLYL PEPTIDES AND SIMILAR PEPTIDOMIMETICS | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIËNTENZORG (NL) | 2011-09-01 | — | — | WO | disclosed |
| EP-2307419-A2 | BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS | Codexis, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20100324080-A1 | Benzomorphan Compounds | PURDUE PHARMA L.P. (US) | 2010-12-23 | — | — | US | disclosed |
| EP-2225246-A1 | BENZOMORPHAN COMPOUNDS | Purdue Pharma LP (US) | 2010-09-08 | — | — | EP | disclosed |
| US-20100216726-A1 | Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof | PURDUE PHARMA L.P. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100063300-A1 | BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS | CODEXIS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| WO-2010008828-A2 | BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS | CODEXIS, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| EP-2086958-A2 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | Purdue Pharma LP (US) | 2009-08-12 | — | — | EP | disclosed |
| WO-2009068989-A1 | BENZOMORPHAN COMPOUNDS | PURDUE PHARMA L.P. (DE) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009027820-A2 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. (DE) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063300-A1 | BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS | PREP, PEPD, COASY | ALDH1A1 909/4885 |
| US-20100216726-A1 | Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof | P2RX4, P2RX5, P2RX3 | ALDH1A1 889/4885 |
| US-20100324080-A1 | Benzomorphan Compounds | OPRM1, OPRK1, OPRD1 | ALDH1A1 1221/4885 |
| US-11786481-B2 | Formulation and process for modulating wound healing | SQSTM1, ATG7, TFEB | ALDH1A1 2877/4885 |
| US-20200206154-A1 | Substituted Tolans for the Modulation of Microbial Colonization | LMAN1, DPM1, DSTN | ALDH1A1 1348/4885 |
| US-20210228501-A1 | Formulation and Process for Modulating Wound Healing | ATG7, SQSTM1, ATF4 | ALDH1A1 2362/4885 |
| US-11351126-B2 | Substituted tolans for the modulation of microbial colonization | LMAN1, DPM1, DSTN | ALDH1A1 1348/4885 |
| US-20220296538-A1 | Substituted Tolans for the Modulation of Microbial Colonization | LMAN1, DPM1, DSTN | ALDH1A1 1348/4885 |
| US-20230130617-A1 | PROCESS FOR IMPROVED OPIOID SYNTHESIS | OPRK1, OPRM1, OPRD1 | ALDH1A1 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.